AGR2 diagnostic value in nasopharyngeal carcinoma prognosis
AGR2 diagnostic value in nasopharyngeal carcinoma prognosis
复制标题
AGR2对鼻咽癌预后的诊断价值
DOI：
10.1016/j.cca.2017.12.023
复制
发表时间：
2018-09-01
影响因子：
5
通讯作者：
Tang, Faqing
中科院分区：
文献类型：
--
作者：
Li, Yuejin;Wang, Weiwei;Tang, Faqing
背景：前梯度蛋白(AGR)2在肿瘤患者血清中的浓度升高，在某些肿瘤中的诊断和预后意义被评价，以往的研究表明，AGR2在鼻咽癌活检组织中高表达。方法：42例健康志愿者、34例乳腺癌患者和124例鼻咽癌患者的血清标本来自健康志愿者、乳腺癌患者和鼻咽癌患者。同期收集鼻咽冰冻标本79例，其中鼻咽癌组织65例，正常鼻咽组织14例。采用酶联免疫吸附试验(EL ISA)检测鼻咽癌患者血清中AGR2的浓度，实时定量RT-PCR法检测冰冻组织中AGR2基因的表达。结果：实时定量RT-PCR结果显示鼻咽癌组织中AGR2基因的表达水平明显高于正常鼻咽组织(p<；0.05)。酶联免疫吸附试验结果显示，鼻咽癌患者血清中AGR2的浓度显著高于健康人群(p<；0.05)。AGR2的表达与肿瘤转移(TNM)分级(p<；0.05)和复发(p<；0.05)相关。此外，高浓度AGR2患者的累积生存率显著低于低浓度AGR2患者(p<；0.05)，而累积危险率显著高于低浓度AGR2患者(p<；0.05)。结论：血清AGR2可作为判断鼻咽癌临床预后的血清标志物。然而，血清AGR2水平不能为肿瘤的鉴别诊断提供临床上的优势。
Background: Anterior Gradient (AGR) 2 concentration increases in the serum of tumor patients, and their diagnostic and prognostic significances were evaluated in some tumors, The previous works showed that AGR2 high express in nasopharyngeal carcinoma (NPC) biopsy tissues. However, whether AGR2 serves as a diagnostic and prognostic marker for NPC remains unclear.Methods: 42 healthy volunteers, 34 breast cancer patients and 124 NPC patients were enrolled into this study, and the serum samples were collected from these healthy volunteers, breast cancer patients and NPC patients. Concomitantly, 79 frozen nasopharyngeal specimens consisted of 65 NPC tissues and 14 normal nasopharyngeal tissues were enrolled in the observation. The enzyme linked immunosorbent assay (ELISA) was used to estimate AGR2 concentration in the serum samples, and AGR2 mRNA expressions in the frozen tissue samples were detected by real time RT-PCR.Results: The real time RT-PCR results showed that AGR2 mRNA level was increased in NPC tissues compared with the normal nasopharyngeal tissues (p < 0.05). The ELISA data showed that AGR2 concentration in NPC serum was significantly higher in NPC patient serums than that in the health population (p < 0.05). And, AGR2 expression showed a correlation with tumor node metastasis (TNM) grade (p < 0.05) and Recurrence (p < 0.05). Moreover, the cumulative survival rate of patients with high concentration of AGR2 was significantly lower than that of patients with low concentration of AGR2 (p < 0.05), and the cumulative hazard rate of patients with high concentration of AGR2 was significantly higher than that with low concentration of AGR2 (p < 0.05).Conclusion: Serum AGR2 can be used as a serum marker for clinical prognosis of nasopharyngeal carcinoma. However, serum AGR2 levels could not provide advantages in clinical practice for the differential diagnosis of cancer.